Strides Pharma Science Limited

BSE: 532531 NSE: STAR
Strides Pharma Science Limited - pharma in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1990PLC057062 Incorporated 28 June 1990 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: STAR · BSE: 532531 Public Limited Company pharma Fortune India 500 · #320
Data last updated
Market Cap
₹10,077 Cr
STAR · NSE
Share Price
₹1,085.60
-0.70% today
Revenue
₹4,859 Cr
FY 2025-26 · +6.4% YoY
EBITDA
₹898 Cr
Margin 18.5%
Net Profit
₹566 Cr
FY 2025-26 · -83.9% YoY
P/E (TTM)
16.2x
P/B 3.0x
ROE
20.3%
ROCE 17.7%
Debt / Equity
0.64
Interest cover 25.6x

About Strides Pharma Science Limited

Data last updated:

Strides Pharma Science Limited is a public limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 June 1990 and has been in existence for over 36 years.

Strides Pharma Science is ranked #320 on the Fortune India 500 (2025). Its director Arun Kumar Pillai is #551 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH1990PLC057062. Its GSTIN is 27AADCS8104P1ZX (Maharashtra). The company holds 25 GST registrations, of which 6 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532531 and NSE: STAR.

The company has an authorised share capital of ₹218.37 Cr and a paid-up capital of ₹92.17 Cr. It was formerly known as Strides Pharma Sciences Limited and Strides Shasun Limited. It is led by directors including Badree Komandur (Managing Director) and Venkata Seetharama Raju Pakalapati (Whole-Time Director).

Its last annual general meeting (AGM) was held on 14 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sector 30, Thane, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹4,858.68 Cr, a growth of 6.4% compared to the previous year. For the same year it recorded a net profit of ₹566.02 Cr (net margin 11.6%) and EBITDA of ₹898.44 Cr (EBITDA margin 18.5%). The net worth stands at ₹3,107.56 Cr (up 21.8% YoY). Total assets are valued at ₹5,064.9 Cr (up 10.2% YoY).

The company has about 2,152 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.

The company is associated with 1 brand: Strides Pharma Science. As per MCA filings, the company has open charges of ₹1,905.26 Cr and satisfied charges of ₹11,468 Cr on record. Court records list 190 cases involving the company, including 107 filed by the company and 87 filed against it; 35 cases are pending. The company has 148 deals on record (123 market trades, 15 secondary share transfers, 8 funding rounds), with disclosed funding of ₹392.69 Cr; the latest was in October 2025. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Aristo Pharmaceuticals Private Limited with revenue of ₹5,363.3 Cr. The company has 37 MSME Form 1 returns on record between 2019 and 2024, listing 45,277 overdue payments to 691 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website strides.com.

Company details

CIN L24230MH1990PLC057062
Registration Number 057062
Incorporation Date 28 June 1990
ROC Mumbai
Listing Status Listed - Listed on NSE (STAR); Listed on BSE (532531)
Company Status Active
Date of Last AGM 14 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Strides Pharma Science has undergone 7 name changes throughout its history. The current legal name is Strides Pharma Science Limited.

Company NameStatus
Strides Pharma Science LimitedCurrent
Strides Pharma Sciences LimitedPrevious
Strides Shasun LimitedPrevious
Strides Arcolab LimitedPrevious
Strides Pharma LimitedPrevious
Strides Pharmaceuticals LimitedPrevious
Strides Pharmaceuticals Private LimitedPrevious
Strides LimitedPrevious
Key People
Badree Komandur Managing Director Venkata Seetharama Raju Pakalapati Whole-Time Director Vikesh Kumar Cfo

Recognitions & Rankings of Strides Pharma Science

Fortune India 500 2025 edition
Rank#320
Total income
₹8,105 Cr
Profit
₹3,593 Cr
Last year #497
India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Strides Pharma Science Limited's registered office is in Thane, Maharashtra. Its website is strides.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    strides.com
  • Social Media
  • Registered Address
    Cyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Strides Pharma Science Limited, buy the company report.

Comprehensive company report
Strides Pharma Science Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Strides Pharma Science operates one associated brand: Strides Pharma Science. Each brand links to its own profile.

BrandDescriptionWebsite
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.strides.com

Business activity

The main business activity of Strides Pharma Science is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Strides Pharma Science Limited, buy the company report.

Financials of Strides Pharma Science Limited

FY 2025-26 filings available

Strides Pharma Science Limited reported revenue of ₹4,858.68 Cr (up 6.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,859 Cr
+6.4% YoY
EBITDA
₹898 Cr
+18.2% YoY
Profit After Tax
₹566 Cr
-83.9% YoY
Net Worth
₹3,108 Cr
+21.8% YoY
Total Assets
₹5,065 Cr
+10.2% YoY
Total Debt
₹1,758 Cr
-6.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,8594,5653,8903,6883,0703,3162,752
Revenue growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%-
EBITDA898760339(10.19)(431)443214
EBITDA margin+18.5%+16.7%+8.7%-0.3%-14.0%+13.4%+7.8%
Profit before tax6693,675(65.21)(268)(653)28941.92
Net profit5663,521149(190)(228)22762.43
Net profit margin+11.7%+77.1%+3.8%-5.1%-7.4%+6.8%+2.3%
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
Balance sheet
Total assets5,0654,5954,6945,2905,5315,4864,963
Net worth3,1082,5522,1262,2122,3592,7772,527
Total debt1,7581,8802,5173,0303,0252,3482,235
Cash & bank213137191316187180237
Net working capital1,8721,6951,7581,8881,9531,2351,085
Cash flow
Cash from operations70368470144.41(258)481205
Cash from investing(173)(90.25)(150)302(119)(522)1,321
Cash from financing(453)(643)(693)(214)421(15.80)(1,709)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2651,3231,1951,2211,1201,1901,1541,167
Revenue growth (YoY)+13.0%+11.2%+3.6%+4.6%+6.2%---
Other income68.099.5810727.148.6815.116.5728.41
EBITDA228233233222210190208180
EBITDA margin+18.1%+17.6%+19.5%+18.2%+18.7%+16.0%+18.0%+15.4%
Depreciation56.4053.2550.6249.6448.8948.8648.4248.45
Interest40.5641.5843.3846.1347.4650.3252.1873.82
Profit before tax20014824515312210611486.21
Tax34.1318.7737.3621.5916.4520.7623.8013.94
Net profit16512920813210685.6290.0672.27
EPS (₹)17.0213.7721.9213.8410.818.929.557.80
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1802,1391,8661,8541,9791,8581,692
Revenue growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%-
EBITDA28526214583.4876.62159204
EBITDA margin+13.1%+12.3%+7.8%+4.5%+3.9%+8.6%+12.1%
Profit before tax2032,90545.88(64.75)21.50112136
Net profit73.562,88650.0721.0117674.98117
Net profit margin+3.4%+134.9%+2.7%+1.1%+8.9%+4.0%+6.9%
EPS (₹)19.92313.164.850.5220.078.7213.43
Balance sheet
Total assets4,5484,4485,2634,9034,7254,3774,085
Net worth3,2843,1933,5283,4553,4073,2483,159
Total debt1,1841,2021,6881,4141,284917902
Cash & bank40.6830.5011585.5814.4573.04110
Net working capital1,5261,5621,7721,4091,266899804
Cash flow
Cash from operations278421(14.01)242(283)283138
Cash from investing(69.07)(138)(68.69)(183)18.78(276)62.83
Cash from financing(199)(370)93.3410.82251(48.64)(204)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue583606554522499556551520
Revenue growth (YoY)+16.9%+9.0%+0.5%+0.5%-14.9%---
Other income77.883.9710314.091.7612.122.4323.55
Total expenses522531472460431488477464
EBITDA61.1274.4081.2062.2267.2367.9374.0855.36
EBITDA margin+10.5%+12.3%+14.7%+11.9%+13.5%+12.2%+13.4%+10.7%
Depreciation25.7325.1922.4021.5122.1422.3720.9220.70
Interest28.5126.6627.2529.4130.4529.3634.2141.83
Profit before tax84.7626.5213525.3916.4028.3221.3816.38
Tax11.8310.1512.91(6.65)3.0512.196.44(0.87)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2651,3231,1951,2211,1201,1901,1541,167
Revenue growth (YoY)+13.0%+11.2%+3.6%+4.6%+6.2%---
Other income68.099.5810727.148.6815.116.5728.41
EBITDA228233233222210190208180
EBITDA margin+18.1%+17.6%+19.5%+18.2%+18.7%+16.0%+18.0%+15.4%
Depreciation56.4053.2550.6249.6448.8948.8648.4248.45
Interest40.5641.5843.3846.1347.4650.3252.1873.82
Profit before tax20014824515312210611486.21
Tax34.1318.7737.3621.5916.4520.7623.8013.94
Net profit16512920813210685.6290.0672.27
EPS (₹)17.0213.7721.9213.8410.818.929.557.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,8594,5653,8903,6883,0703,3162,752
Revenue growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%-
Other income1513,35689.85247188203157
Total expenses3,9603,8053,5513,6993,5012,8732,538
Employee cost929863737732647550443
EBITDA898760339(10.19)(431)443214
EBITDA margin+18.5%+16.7%+8.7%-0.3%-14.0%+13.4%+7.8%
Depreciation202192214243233206174
Interest179249280261177150156
Profit before tax6693,675(65.21)(268)(653)28941.92
Tax94.1777.5229.11(55.30)(178)31.6511.33
Net profit5663,521149(190)(228)22762.43
Net profit margin+11.7%+77.1%+3.8%-5.1%-7.4%+6.8%+2.3%
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital92.1792.1691.9090.3089.7989.6889.57
Reserves & surplus3,0152,4602,0342,1052,2692,6872,438
Shareholders' funds (net worth)3,1082,5522,1262,2122,3592,7772,527
Minority interest41.7734.63(53.86)(39.38)24.0937.3467.24
Secured loans1,4991,6502,2412,5682,1092,0331,955
Unsecured loans259229276461916316279
Total debt1,7581,8802,5173,0303,0252,3482,235
Total liabilities5,0654,5954,6945,2905,5315,4864,963
Assets
Gross block3,3042,9112,8873,3393,2462,9382,631
Net block2,1011,8991,8652,3112,3472,2192,099
Capital work in progress447207162151291447413
Investments291409303490540697549
Inventories1,6351,2781,1261,1471,1741,201783
Sundry debtors1,2891,2031,1421,2991,2071,107932
Cash & bank balances213137191316187180237
Loans & advances476412404431793230302
Total current assets3,6133,0292,8633,1933,3622,7182,253
Total current liabilities1,7421,3351,1061,3041,4091,4831,168
Net working capital1,8721,6951,7581,8881,9531,2351,085
Total assets5,0654,5954,6945,2905,5315,4864,963
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash113161304171126182366
Net cash from operating activities70368470144.41(258)481205
Net cash from investing activities(173)(90.25)(150)302(119)(522)1,321
Net cash from financing activities(453)(643)(693)(214)421(15.80)(1,709)
Net change in cash76.13(48.46)(142)13344.90(56.40)(184)
Closing cash213137191316187180237
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.4%+17.4%+5.5%+20.1%-7.4%+20.5%-
EBITDA growth+18.2%+124.5%+3424.8%+97.6%-197.3%+107.0%-
PBT growth-81.8%+9998.0%+75.6%+59.0%-+590.3%-86.2%
Net income growth-83.9%+2269.5%+178.3%+16.8%-200.6%+263.1%-
Revenue CAGR (3Y)+9.6%+14.1%+5.5%+10.3%+12.1%+5.2%-0.0%
EBITDA CAGR (3Y)---8.5%--+8.1%-23.4%
Profitability & leverage
Net income margin+11.8%+78.8%-2.4%-5.8%-15.5%+7.8%+1.1%
Return on capital employed+17.7%+14.3%0.0%0.0%-4.4%+7.3%+5.1%
Return on net worth+20.3%+150.7%0.0%0.0%-9.4%+8.1%+2.2%
Debt / equity0.640.941.281.321.050.861.05
Long-term debt / equity0.220.290.480.520.410.370.51
Interest cover25.6543.80223.89-103.04-26.6363.46387.65
Efficiency & per share
Fixed asset turnover1.561.571.251.120.991.190.81
Inventory turnover3.343.803.423.182.593.343.32
Debtors turnover3.903.893.192.942.653.252.87
EPS (₹)60.34389.90(7.68)(22.44)(51.25)29.934.06
Dividend per share (₹)5.004.002.501.500.002.5014.00
Book value per share (₹)337.14276.88231.28243.09262.70309.62282.19
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue583606554522499556551520
Revenue growth (YoY)+16.9%+9.0%+0.5%+0.5%-14.9%---
Other income77.883.9710314.091.7612.122.4323.55
Total expenses522531472460431488477464
EBITDA61.1274.4081.2062.2267.2367.9374.0855.36
EBITDA margin+10.5%+12.3%+14.7%+11.9%+13.5%+12.2%+13.4%+10.7%
Depreciation25.7325.1922.4021.5122.1422.3720.9220.70
Interest28.5126.6627.2529.4130.4529.3634.2141.83
Profit before tax84.7626.5213525.3916.4028.3221.3816.38
Tax11.8310.1512.91(6.65)3.0512.196.44(0.87)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1802,1391,8661,8541,9791,8581,692
Revenue growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%-
Other income1232,87312884.0712311793.07
Total expenses1,8951,8771,7211,7711,9021,6981,487
Employee cost382378349267272273230
EBITDA28526214583.4876.62159204
EBITDA margin+13.1%+12.3%+7.8%+4.5%+3.9%+8.6%+12.1%
Depreciation91.2484.6187.4193.6210499.3494.24
Interest11414613913974.2465.3466.84
Profit before tax2032,90545.88(64.75)21.50112136
Tax19.4718.931.34(69.44)(159)33.3916.17
Net profit73.562,88650.0721.0117674.98117
Net profit margin+3.4%+134.9%+2.7%+1.1%+8.9%+4.0%+6.9%
EPS (₹)19.92313.164.850.5220.078.7213.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital92.1792.1691.9090.3089.7989.6889.57
Reserves & surplus3,1913,1013,4363,3483,3163,1583,069
Shareholders' funds (net worth)3,2843,1933,5283,4553,4073,2483,159
Secured loans9951,0241,5271,2541,122792846
Unsecured loans19017816116016212555.18
Total debt1,1841,2021,6881,4141,284917902
Total liabilities4,5484,4485,2634,9034,7254,3774,085
Assets
Gross block1,5801,4931,4601,1961,1421,0991,020
Net block785767747597617644651
Capital work in progress18110610755.3855.72111112
Investments1,8681,8482,3642,4922,4002,3952,171
Inventories580432498491513689463
Sundry debtors1,5211,4531,5651,3081,296822656
Cash & bank balances40.6830.5011585.5814.4573.04110
Loans & advances231230233242151160167
Total current assets2,3742,1462,4112,1261,9751,7441,396
Total current liabilities847583639717709845592
Net working capital1,5261,5621,7721,4091,266899804
Total assets4,5484,4485,2634,9034,7254,3774,085
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.3392.7582.1112.1225.3066.8269.91
Net cash from operating activities278421(14.01)242(283)283138
Net cash from investing activities(69.07)(138)(68.69)(183)18.78(276)62.83
Net cash from financing activities(199)(370)93.3410.82251(48.64)(204)
Net change in cash9.84(86.42)10.6569.98(13.18)(41.52)(3.09)
Closing cash40.6830.5011585.5814.4573.04110
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.9%+14.7%+0.6%-6.3%+6.5%+9.8%-
EBITDA growth+8.6%+80.8%+73.9%+9.0%-51.9%-22.1%-
PBT growth-93.0%+6232.0%+9998.0%--80.7%-18.2%+25.2%
Net income growth-97.5%+5664.6%+138.3%-88.1%+134.7%-35.8%-
Revenue CAGR (3Y)+5.5%+2.6%+0.2%+3.1%+8.8%+8.1%+7.0%
EBITDA CAGR (3Y)+50.6%+50.7%-3.0%-25.8%-16.5%-1.0%+23.5%
Profitability & leverage
Net income margin+8.4%+134.9%+2.4%+0.3%+9.1%+4.2%+7.1%
Return on capital employed+4.8%+4.6%+2.4%+1.9%+1.9%+4.2%+5.0%
Return on net worth+2.3%+85.9%+1.4%+0.6%+5.3%+2.4%+3.8%
Debt / equity0.370.430.440.390.330.280.27
Long-term debt / equity0.050.060.080.070.050.030.01
Interest cover58.7082.06241.48-1,367.65-267.53109.1260.64
Efficiency & per share
Fixed asset turnover1.421.451.411.591.771.751.82
Inventory turnover4.314.603.773.693.293.233.61
Debtors turnover1.471.421.301.421.872.512.73
EPS (₹)19.92313.164.850.5220.078.7213.43
Dividend per share (₹)5.004.002.501.500.002.5014.00
Book value per share (₹)356.23346.42383.84380.71379.36362.18352.68

To see the full year-wise statements and ratios of Strides Pharma Science Limited, buy the company report.

Board of directors and KMP of Strides Pharma Science Limited

Strides Pharma Science Limited currently reports 9 directors and 2 key managerial personnel. 19 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Homi Rustam Khusrokhan
Also directs: Neuland Laboratories Ltd., The Anglo Scottish Education Society
Director18 May 20179 Years 5 MonthsCurrent
Vikesh KumarCfo01 Jun 20242 Years 4 MonthsCurrent
Venkata Seetharama Raju Pakalapati
Also directs: Sunspire Life Sciences Private Limited
Whole-Time Director01 Jun 20260 Years 4 MonthsCurrent
Manjula RamamurthyCompany Secretary03 Feb 20179 Years 8 MonthsCurrent
Badree KomandurManaging Director18 May 20179 Years 5 MonthsCurrent
Subir Chakraborty
Also directs: Ifb Industries Ltd
Director01 Jun 20242 Years 4 MonthsCurrent
Showing 6 of 11 current directors and KMP. View all directors and KMP

Peer comparison

Strides Pharma Science Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Aristo Pharmaceuticals Private Limited₹5,363.3 Cr (FY 2025)5.0%Mumbai, Maharashtra, India
Usv Private Limited₹5,202.13 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Strides Pharma Science Limitedthis company₹4,858.68 Cr (FY 2026)₹566.02 Cr11.6%6.4%2,152Thane, Maharashtra, India
Eugia Pharma Specialities Limited₹4,828.71 Cr (FY 2025)12.0%Hyderabad, Telangana, India
Natco Pharma Limited₹4,784 Cr (FY 2025)16.0%Hyderabad, Telangana, India
Ajanta Pharma Limited₹4,742.6 Cr (FY 2025)10.0%Mumbai, Maharashtra, India
Apl Healthcare Limited₹4,412.92 Cr (FY 2025)39.0%Hyderabad, Telangana, India
Akums Drugs and Pharmaceuticals Limited₹4,170.28 Cr (FY 2025)-1.0%Delhi, India
J B Chemicals and Pharmaceuticals Limited₹3,956.31 Cr (FY 2025)12.0%Ahmedabad, Gujarat, India
Glaxosmithkline Pharmaceuticals Limited₹3,895.14 Cr (FY 2025)9.0%Mumbai, Maharashtra, India

To see the full peer comparison of Strides Pharma Science Limited, buy the company report.

Auditor

Strides Pharma Science Limited is audited by B S R & Co. LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2024101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 27.90%, foreign institutional investors hold 28.40%, domestic institutional investors hold 15.40% and retail and other public shareholders hold 28.30%.

Promoters: 27.90%DII (Domestic Institutional): 15.40%FII (Foreign Institutional): 28.40%Retail & Others: 28.30%
Sep 2026
QUARTER
27.90% Promoters
15.40% DII (Domestic Institutional)
28.40% FII (Foreign Institutional)
28.30% Retail & Others
Promoter holding - history
Now 27.90% · Sep 2026High 27.90% · Dec 2025Low 27.90% · Dec 2025
26%26.8%27.5%28.3%29%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 27.90%Mar 2026: 27.90%Jun 2026: 27.90%Sep 2026: 27.90%27.90%27.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters27.90%27.90%27.90%27.90%
Public72.10%72.10%72.10%72.10%

Charges & borrowings

Open charges
₹1,905.26 Cr
Satisfied charges
₹11,468 Cr
Breakdown by lending institutions
Others₹1,904.62 Cr
Hdfc Bank Limited₹0.64 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
24 Jul 2026101356437Others₹75 CrOpen
20 Oct 2023100937632Hdfc Bank Limited₹64.39 LakhOpen
19 Jul 2016100062848Others₹1,829.62 CrOpen
27 Mar 2025101075943Others₹100 CrSatisfied
10 Feb 2025101057359Karnataka Bank Ltd.₹100 CrSatisfied

To see the full charge records of Strides Pharma Science Limited, buy the company report.

Total charge records: 275 View all charges

Deals & funding

Strides Pharma Science Limited has 148 deals on record (123 market trades, 15 secondary share transfers, 8 funding rounds), with disclosed funding of ₹392.69 Cr; the latest was in October 2025.

Total deals
148
Market trades
123
Secondary share transfers
15
Funding rounds
8
QIPs
2
Disclosed funding
₹392.69 Cr

Deals on record (5 of 148)

WhenDealAmountParties
Oct 2025Market trade₹54.33 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jan 2025Market trade₹28.97 CrBuyer: Authum Investment & Infrastructure Limited
Dec 2023Market trade₹15.93 CrBuyer: Pace Stock Broking Services Private Limited
Seller: Shasun Enterprises LLP
Dec 2023Market trade₹31.43 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Nov 2023Market trade₹44.6 CrBuyer: an individual
Seller: Pronomz Ventures LLP

To see the full deal history of Strides Pharma Science Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Strides Pharma Science Limited was last rated by Icra on 24 Mar 2022.

Rating agencyRated onRating
Icra24 Mar 2022

To see the full credit ratings and regulatory alerts of Strides Pharma Science Limited, buy the company report.

MSME payment delays

Strides Pharma Science Limited has 37 MSME Form 1 returns on record between 2019 and 2024, listing 45,277 overdue payments to 691 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 691)

SupplierAmount dueDue sinceReported on
NGPL Paper Pack Private Limited
Accupak Private Limited
Orbit Science
Enaviya Information Technologies Private Limited
Allstar Shipping Private Limited

To see the full MSME payment records of Strides Pharma Science Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Strides Pharma Science has 3 subsidiary companies and 3 associated companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

3
Subsidiary companies
3
Associated companies
Key subsidiaries
Company NameCINShares held

Employees & EPFO

Strides Pharma Science Limited has a workforce of 2,152 employees on its EPFO records as of Nov 19, 2024, across 3 active EPFO establishments.

Employee count
2,152
Active EPFO establishments
3
Employee growth
1.94%

GST

Strides Pharma Science has 25 GST registrations: 6 active and 19 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
25
Active
6
Cancelled / inactive
19
GSTINStateStatusRegistered on
27AADCS8104P1ZXMaharashtraActive01 Jul 2017
29AADCS8104P1ZTKarnatakaActive01 Jul 2017
33AADCS8104P1Z4Tamil NaduActive01 Jul 2017
34AADCS8104P2Z1PuducherryActive01 Jul 2017

To see the full GST registrations and return filing status of Strides Pharma Science Limited, buy the company report.

Recent activity

Strides Pharma Science Limited has 30 board changes on record since 2008: 11 appointments and 19 cessations. The latest: Venkata Seetharama Raju Pakalapati was appointed as Whole-Time Director on 01 Jun 2026.

AGM
Strides Pharma Science Limited last Annual general meeting of members was held on 14 Aug 2026 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101356437 was registered on 24 Jul 2026.
Appointed
Venkata Seetharama Raju Pakalapati was appointed as Whole-Time Director.
Charges
A charge with Others of Rs. 1,829.62 Cr registered on 19 Jul 2016 with Charge ID 100062848 was modified on 15 May 2026.
Filing
Strides Pharma Science Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
A charge registered on 03 Nov 2020 via Charge ID 100389968 with Hdfc Bank Limited was fully satisfied on 09 Nov 2025.
Charges
A charge registered on 19 Sep 2023 via Charge ID 100793392 with Others was fully satisfied on 27 Oct 2025.
Charges
A charge registered on 10 Feb 2025 via Charge ID 101057359 with Karnataka Bank Ltd. was fully satisfied on 30 Sep 2025.
Charges
A charge registered on 27 Mar 2025 via Charge ID 101075943 with Others was fully satisfied on 17 Sep 2025.
Charges
A charge registered on 26 Sep 2024 via Charge ID 100988139 with State Bank Of India was fully satisfied on 29 May 2025.
Appointed
Arun Kumar Pillai was appointed as Director.
Charges
A charge with Others amounted to Rs. 100.00 Cr with Charge ID 101075943 was registered on 27 Mar 2025.

687 earlier events are in the company report.

News

Frequently asked questions

Strides Pharma Science is an active public limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 June 1990 (36+ years old) and is registered under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR.

Strides Pharma Science reported revenue of ₹4,858.68 Cr for FY 2025-26 (up 6.4% YoY) based on consolidated financials.

Strides Pharma Science has 11 current directors and KMP:

The latest financial statements of Strides Pharma Science on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 14 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Strides Pharma Science is 27AADCS8104P1ZX, registered in Maharashtra. The company has 25 GST registrations in all, of which 6 are active and 19 are cancelled or inactive. Other active GSTINs include 29AADCS8104P1ZT (Karnataka), 33AADCS8104P1Z4 (Tamil Nadu), 34AADCS8104P2Z1 (Puducherry).

The CIN (Corporate Identification Number) of Strides Pharma Science is L24230MH1990PLC057062. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Strides Pharma Science is a listed company as per MCA records. Its shares are listed on both BSE (code: 532531) and NSE (symbol: STAR).

Strides Pharma Science has 190 court cases on record: 107 filed by the company and 87 filed against it. 35 are pending. Most are in the high courts.

Strides Pharma Science was incorporated on 28 June 1990, making it 36+ years old. It is registered with the Registrar of Companies, Mumbai.

Strides Pharma Science has 148 deals on record (123 market trades, 15 secondary share transfers, 8 funding rounds), with disclosed funding of ₹392.69 Cr; the latest was in October 2025.

The peers of Strides Pharma Science by revenue are Aristo Pharmaceuticals Private Limited, Usv Private Limited, Eugia Pharma Specialities Limited, Natco Pharma Limited, Ajanta Pharma Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Venkata Seetharama Raju Pakalapati was appointed as Whole-Time Director on 01 Jun 2026. Arun Kumar Pillai was appointed as Director on 05 Apr 2025. Mukta Malik Arora was appointed as Director on 01 Feb 2025. Strides Pharma Science has 30 board changes on record in total.